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SUMMARY 
 
Osteoarthritis (OA) is a progressive joint disease leading to the destruction of joint structures, which in turn 
causes severe and chronic pain to the patient. Since OA is a troubling and disruptive disease, numerous researches have 
been done into diagnosing this disease, both in the early and the late stages of the disease. Diagnostic modalities such 
as radiography, computed-tomography (CT), micro-computed tomography (µ-CT), and magnetic resonance imaging 
(MRI) have been used in OA research. Not only that, more advance measurements and criteria have been established to 
standardize OA research. Currently, the OA research has been delving into proteomic studies to search for potential 
disease biomarkers. Biomarkers such as urinary C-terminal telopeptide of collagen type 2 (uCTX-II) and cartilage 
oligometric protein (COMP) have shown potential to be both diagnostic and prognostic biomarkers.  For this review 
paper, the developments in diagnostic modalities are discussed focusing more on proteomic and biomarker studies.  
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INTRODUCTION 
 
Osteoarthritis (OA) is a degenerative joint disease 
characterised by metabolic, biochemical, and structural 
changes of articular cartilage, subchondral bone, synovial 
membrane, and periarticular structures (Yamagiwa et al., 
2003; Castañeda et al., 2012, Lee et al., 2013). Initially, 
OA was thought to be a disease of the cartilage, however 
as more and more extensive studies and researches were 
done over the years and it was unraveled that OA is a 
disease of organ level failure which includes ligaments, 
muscles, nerve, bone, and meniscus (Brandt et al., 2006). 
OA is a heterogeneous disease with many contributing 
risk factors that are able to induce or accelerate disease 
progression (Sowers & Karvonen-Gutierrez, 2010; 
Castañeda et al., 2012). There are various contributing 
risk factors which can be broadly categorized into non-
genetic and genetic factors (Sharma et al., 2013). There 
are several on-going theories on aetiopathogenesis of OA 
that are currently being debated whether it is a cartilage 
or bone driven disease (Buckwalter et al., 2013; Houard 
et al., 2013). Despite that argument, evidence suggests 
that the pathological changes occurring in the 
osteoarthritic joint eventually leads to its destruction and 
failure (Sokolove & Lepus, 2013). Simply put, OA is a 
troubling and painful disease that comes and never leaves 
and as it progresses, the pain worsens and this will affect 
the quality of life in one way or another.  
There are different definitions for early OA but for 
this article, a general description of early OA is classified 
based on three criteria (Luyten et al., 2012): (i) pain in the 
knee, (ii) standard radiographs with Kellgren-Lawrence 
grade 0 or I or II (osteophytes only) and (iii) at least one 
of the two following structural criteria, arthroscopic 
findings of cartilage lesions or magnetic resonance 
imaging (MRI) findings demonstrating articular cartilage 
 
* Corresponding author: Dr Lau Seng Fong (S.F. Lau);  
Phone No: 603-8609 3927; Email: lausengfong@upm.edu.my 
degeneration and/or meniscal degeneration, and/or 
subchondral bone marrow lesions (BMLs). 
 
Diagnostic modalities of osteoarthritis  
 
Currently, many methods of diagnosis of OA had 
been developed over the decades. However, for a patient 
suspected of OA to be first presented, they would need to 
have the main symptoms of joint pain, especially 
unbearable after weight-bearing activities and loss of 
range of mobility to carry out day-to-day activities 
(Bijlsma et al., 2011).  
 
Radiography  
 
Radiography is usually the first line diagnostic tool 
for diagnosing OA (Kim et al., 2015). Plain radiography 
of the joint will be taken to rule in or to rule out OA. It is 
fast, low cost, and easily accessible in treatment centers. 
Plain radiograph is the gold standard in imaging 
osteoarthritic joints (Bijlsma et al., 2011). In 1956, 
Kellgren and Lawrence introduced the guidelines of 
radiological grading of OA (Table 1) and these guidelines 
are still being used up till now (Nojiri et al., 2006; 
Fernandes et al., 2015; Li et al., 2015; Van Spil et al., 
2015). Albeit being a very useful and accessible tool to 
diagnose OA, radiograph has its limitations of producing 
two dimensional image and limited ability to visualize the 
articular cartilage, synovium, menisci, and other non-
osseous joint structures. In addition, small osteophytes 
might not visualised in radiographs if hidden by overlying 
boney structure in radiographs. If more images were 
taken in various positions, it will subject the patient to 
more exposure to radiation. Radiography is more useful 
in detecting OA in the late stages, where osseous changes 
have already taken place compared to early OA where 
only subtle changes occur (Hayashi et al., 2014; Kim et 
al., 2015). 
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Table 1. Kellgren and Lawrence grading system for 
osteoarthritis 
Classification Radiographic findings 
Grade 0 No radiographic features of OA are 
present 
Grade 1 Doubtful joint space narrowing (JSN) 
and possible osteophytic lipping 
Grade 2 Definite osteophytes and possible JSN 
on anteroposterior weight-bearing 
radiograph 
Grade 3 Multiple osteophytes, definite JSN, 
sclerosis, possible bony deformity 
Grade 4 Large osteophytes, marked JSN, 
severe sclerosis and definite bony 
deformity 
 
Computed tomography  
 
As technology advances, better machines and 
equipment have been engineered. Computed tomography 
(CT) is a technique that is well suited for bone imaging. It 
is a better diagnostic tool in comparison to radiography as 
the images are not superimposed and can be evaluated in 
different reconstructed views. Currently, CT has been 
widely used in the study of changes of different structures 
of the joints in events of OA. It produces three 
dimensional (3D) images with the option of adding 
contrast agent to enhance certain regions especially the 
cartilage (Bijlsma et al., 2011; Siebelt et al., 2011). On 
the downside, it is more costly and only available in 
certain hospitals and treatment centers. Not to mention, 
the patient is exposed to higher dosage of radiation. 
Furthermore, the spatial resolution of the commercial CT 
makes its impractical to be used for imaging laboratory 
animals. 
 
Micro-computed tomography  
 
In addition to the traditional CT, micro computed 
tomography (micro-CT) has been further developed for 
the investigation of OA in laboratory animals. Micro-CT 
is a small scale radiographic imaging in 3D with high 
resolution imaging. It has been used in an extensive range 
of OA studies using animal models both ex vivo and in 
vivo, focusing on bone morphology and microarchitecture 
(Bouxsein et al., 2010, Lau et al., 2013). To enhance the 
targeted area such as changes in the articular cartilage or 
subchondral bone, radiopaque contrast agents such as 
barium sulfate (Leng et al., 2008), sodium and 
meglumine ioxaglate (Kotwal et al., 2012; Lau et al., 
2013) had been added in to the bone or joint space in 
order to highlight these specific regions. So far, micro-CT 
has been used more for research purposes rather than for 
clinical diagnosis. Despite that, the results has been 
translated into the clinical applied CT arthrography 
(Siebelt et al., 2011) 
As technology progresses, four dimensional (4D) 
micro-CT combines in vivo micro-CT imaging and a 
computational approach for direct visualisation of images. 
By creating 3D spatial and one dimension (1D) temporal 
CT images, this technique has allowed for achieving the 
3D measures comparable to traditional 2D histology with 
the additional capability of temporal characterization of 
the formation, resorption, remodeling, and bone turnover 
events (Birkhold et al., 2015). However, even though 4D 
micro-CT has not yet been applied to the study of OA 
thus far, it is only a matter of time before it is used to 
monitor changes of the articular cartilage and subchondral 
bone. 
 
Magnetic resonance imaging  
 
Magnetic resonance imaging (MRI) has been used 
widely used in the diagnosis of OA. Based on past 
literature, MRI is also an important tool to diagnose and 
stage early OA (Madry et al., 2016). As it is known for its 
ability to image soft tissues, MRI is used in imaging joint 
structures including articular cartilage, menisci, 
ligaments, and synovium. As degeneration of articular 
cartilage is one of the hallmarks of OA progress, MRI has 
been extensively used in many recent OA studies 
(Sharma et al., 2014; Wise et al., 2016). The capability of 
MRI to provide exquisite contrast of the morphological 
and physiological conditions of the articular cartilage had 
shed light in the events of pathogenesis of OA.  
Delayed Gadolinium-enhanced MRI (dGEMRIC) 
has been introduced in OA studies to quantitatively 
estimate glycosaminoglycan content of cartilage (Nojiri et 
al., 2006; Madry et al., 2016). T2 mapping or diffusion-
weighted imaging (DWI) together with MRI was also 
used to provide qualitative and quantitative information to 
evaluate tissue changes and structural integrity (Braun & 
Gold, 2012; Madry et al., 2016). Since MRI has a higher 
sensitivity for the detection of OA as compared to 
radiographs, it has been greatly used for both diagnosing 
and monitoring OA progression, not to mention pre and 
post-operative surgical treatments involving the joint. 
Nonetheless, MRI has its disadvantages in its high cost, 
acquisition time, and the need for a skilled operator due to 
its complex techniques. 
Concurrently, researchers then turned to proteomics 
to search for disease biomarkers related to OA. A disease 
biomarker can be defined as a measurable indicator of a 
specific biological state, particularly the one that provides 
essential details about the risk, presence or stage of a 
disease (Rifai et al., 2006). It can be used for very broad 
clinical applications, both for diagnostic purposes and as 
a prognostic indicator. Currently, disease biomarkers are 
the most promising method for diagnosing early OA 
(Madry et al., 2016). More on the current proteomic 
studies and possible biomarkers will be discussed.  
 
Proteomic studies in diagnosing early OA 
 
The Biomarkers Definition Working Group defined 
biomarkers as a characteristic that is objectively measured 
and evaluated as an indicator of a normal biological 
process, pathogenic process, or pharmacologic response 
to a therapeutic intervention. As comprehensive 
proteomic studies uses clinical samples such as tissues or 
body fluids, it is better defined as clinical proteomics 
(Paik et al., 2008). In clinical proteomics, the main aim is 
the discovery of biomarkers, specifically disease 
biomarkers. 
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The process in proteomics depends on the 
separation of a large number of proteins which are 
identified by mass spectrometry (MS) (Ruiz-Romero and 
Blanco, 2010). Separation of proteins can be carried out 
with methods using two dimensional gel electrophoresis 
(2DGE) and liquid chromatography (LC). These 
individual proteins could be identified via MS. MS 
protein identification is performed through a process of 
protein or peptide ionisation, ion separation and lastly 
detected according to the instrument used. Peptide 
ionisation can be done using matrix-assisted laser 
desorption/ionisation (MALDI) source or in solution for 
electrospray ionisation (ESI) sources. Then, these ions are 
separated according to their mass/charge relationships 
(m/z) by using a time-of-flight (TOF), quadrupole or ion 
trap analyser. The ion masses are measured in the 
detectors to form a mass spectrum according to its m/z 
values. These values will then be compared to the 
database to determine the protein identified (Mateos et 
al., 2012; Hrabák et al., 2013).  
Proteomics in OA research is mainly conducted to 
(i) understand the pathophysiology and disease 
mechanism of OA development, (ii) find potential disease 
biomarkers, and (iii) identify new therapeutic targets 
(Gharbi et al., 2011). Proteomic research permits the 
discovery of novel protein biomarkers not only for 
diagnosis but also for the planning of therapeutic 
treatment. These biomarkers will help in developing a 
therapeutic treatment plan that caters to different 
individuals at different stages and progress of the disease 
(Cho, 2007). Proteomics also provides the opportunity for 
the study of novel molecular targets for drug discovery. 
 
 
Selected OA proteomic studies published between 2010 
and 2015 
 
Proteomics research for biomarkers discovery of 
OA can be divided into two approaches which are (i) 
target-specific and (ii) global/non-directed (Ruiz-Romero 
and Blanco, 2010). The target-specific approach focuses 
on particular biomarker/s and often uses antibodies via 
Western blot analysis, enzyme-linked immunosorbent 
assay (ELISA), or antibody arrays (Ruiz-Romero and 
Blanco, 2010). On the other hand, the global or non-
directed approach screens and profiles all proteins that 
were identified. 
Over the years, many methods and strategies were 
developed for uncovering biomarkers in OA. Some of the 
methods and strategies that were used over the last five 
years are listed in Table 2. Several researches on finding 
the potential biomarkers of OA were done using 2DGE 
followed by MS analysis. In addition, various methods of 
sample preparations such as high abundance protein 
depletion were studied before by analysing by MS and 
bioinformatics tools. For example, Bennike (2014) 
prepared his samples with different trypsin digestion 
protocols and later analysed them by high 
resolution/high-accuracy MS systems for shotgun 
proteomic analysis. Another highly popular method is one 
dimensional gel electrophoresis (1DGE) followed by MS 
analysis.  
Other methods that have been popular in this field 
are gel free methods or also known as shotgun 
proteomics. Proteins are separated by high performance 
liquid chromatography (HPLC) followed by MS analysis 
(Gharbi et al., 2011). This method has a higher resolution 
and also easier to perform because the procedures are 
automated.  
 
Table 2. Some of the strategies for proteomic research for osteoarthritis 
Proteomic approaches Mass spectrometer References 
1DGE LC-MS/MS 
 
Garner et al., 2013 
Balakrishnan et al., 2014 
1DGE, In-gel digestion and iTRAQ labeling LC-MS/MS Lourido et al., 2014 
1DGE, Filter-Aided Sample Preparation 
(FASP) Digestion, Urea In-Solution 
Digestion, In-gel digestion 
LC-MS/MS 
 
Bennike et al., 2014 
Bennike et al., 2015 
Western blot Surface enhanced laser 
desorption/ionization 
(SELDI)-TOF-MS 
Han et al., 2012 
2DGE 
 
- 
MALDI-TOF-MS 
 
Kong et al., 2012 
Chiaradia et al., 2012 
Chen et al., 2011 
2D Difference Gel Electrophoresis (2DIGE) 
and Western Blot 
LC-MALDI-TOF/TOF Fernandez-Costa et al., 2012 
 
Nano Liquid Chromatography (nanoLC) and 
Western Blot 
MALDI-TOF/TOF Mateos et al., 2012 
FFPE (formalin-fixed paraffin-embedded)  LC-MS/MS Hayashi et al., 2015 
Protein chip array SELDI-TOF-MS de Seny et al., 2011 
Selected reaction monitoring (SRM) MS Ritter et al., 2014  
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Table 3. Potential biomarkers for osteoarthritis 
 Area Group Potential Biomarkers Function 
Joint 
inflammation 
 
Innate immune 
system 
 
 
Chemokines: 
• Interferon gamma inducible 
protein 10 (CXCL-10) 
•  Serum fractalkine (CX3CL1) 
• SF CXCL12 chemokine ligand 2 
(SF MCP-1/CCL2)  
Act as chemoattractants to guide 
cells to migrate to a specific 
location 
Cytokines: 
• IL-1α 
• IL-18 
• TNF-α (effectively used to 
monitor efficacy of various OA 
treatment in rabbits) 
Small proteins released from 
various cells 
Macrophage: 
• CD14 
• CD163 
Associated with response to 
inflammation 
Complement: 
• C3a 
• C5b-9  
Assists antibodies and 
phagocytic cells with the 
clearance of foreign objects 
C-reactive protein (CRP) Central component of the innate 
immune inflammatory response  
Adipokines/Hormones: 
• Adiponectin  
• Leptin  
• Adipsin  
• Visfatin  
• Estradiol 
• Urinary estrogen metabolite 2-
hydroxyestrone 
Mediates inflammatory effects 
and cartilage catabolism in OA 
Articular 
cartilage 
Structural protein Type II collagen Bind to other matrix 
macromolecules i.e. types IX and 
XI collagen and is critical for 
cartilage stability 
Type II collagen 
degradation 
Helical fragments: 
• Helix-II 
• Coll 2-1 
• Coll 2-1 NO2 
Play a role in inflammatory 
processes and cartilage 
destruction of the joint 
Proteoglycan • ADAMTS4 
• ADAMTS5 
Protein core to which many 
chondroitin and keratin-sulphate 
chains are attached to 
Cartilage 
degradation 
Cartilage oligomeric matrix protein 
(COMP) 
Aids in inflammatory 
proliferation of synovial 
membrane, regulation of fibril 
network and maintain the mature 
collagen network (Sharma et al., 
2013) 
Amino-terminal type II procollagen 
propeptide (PIINP) 
Reflects the rate of synthesis of 
collagen type II 
Carboxy-terminal type II procollagen 
propeptide 
YLK-40 Glycoprotein: 
noncollagenous protein 
Aids in tissue inflammation, 
immunity, and/or remodeling  
J. Vet. Malaysia (2017) 29 (1):7-12 
11 
 
Hyaluronic acid (HA) Provides viscoelasticity of 
synovium fluid and cartilage 
Remodeling of 
calcified cartilage 
C-terminal telopeptide of type II 
collagen (CTX-II) 
Provides strength, integrity and 
maintain shape of tissue 
Cartilage turnover Chondroitin sulfate 846 epitope (CS 
846) 
Provides hydrated gel structure 
of the cartilage 
Synovial fluid Angiogenetic 
factor 
Vascular endothelial growth factor 
(VEGF) 
Increases vascularity within 
articular cartilage 
  Sphingosine 1-phosphate (S1P) Regulation of cyclooxygenase-2 
(COX-2), VEGF, and inducible 
nitric oxide synthase (iNOS), 
MMP-13, and ADAMTS-4 
(cartilage chondrocytes) 
Chondrocytes Osteoblasts RANKL Causes elevated 
osteoclastogenesis during OA 
Bone Bone degradation Amino-terminal type II procollagen 
propeptide (PIINP) 
Reflects the rate of synthesis of 
collagen type II 
Carboxy-terminal type II procollagen 
propeptide 
Anabolic bone 
turnover 
Osteocalcin (OC) Needed for bone mineralization 
and recruitment of osteoblast and 
osteoclast  
Type I collagen 
degradation 
N-terminal type I collagen 
telopeptides (NTX I) 
Maintains bone remodeling 
process 
Subchondral 
bone 
Growth factors • Insulin-like growth-factor 1 (IGF-
1) 
• Transforming growth-factor β 
(TGF β) 
Contributes to bone formation 
Potential biomarker discovery 
 
According to Lotz (2013), suitable biomarkers for 
OA should be structural molecules or a fragment linked to 
cartilage, bone or synovium of the joint which only 
relates to joints specifically that affected the joint. Based 
on the past proteomic studies conducted, many potential 
biomarkers were uncovered. These biomarkers are listed 
in Table 3.   
Disease biomarkers are the future of diagnosing 
OA. From there, a tailored multimodal treatment using 
Disease Modifying OA Drugs (DMOAD) concurrently 
with physiotherapy and muscle strengthening exercise 
can be used to combat this troubling disease. The 
possibility of usage for pinpointing the area of damage, 
the progression of disease, and monitoring the treatment 
outcome is endless and will open doors to many more 
studies.  
Nonetheless, out of these biomarkers which were 
discovered, only a handful showed potential to be 
biomarkers. A few of those included urinary C-terminal 
telopeptide of collagen type 2 (uCTX-II)  and serum 
cartilage oligomeric protein (COMP)  showed high 
potential to be both diagnostic and prognostic biomarkers 
(Dam et al., 2009; Lotz et al., 2013). However, till now, 
there is still no “the one” biomarker that has been 
sufficiently validated to be the gold standard regardless of 
the extensive amount of research that had been done 
(Madry et al., 2016).  
Conversely, there are also limitations to their uses. 
If other physiological and pathological changes do occur 
in other parts of the body other than the joints, systemic 
biomarkers will also be circulated might interfere with or 
provide a false diagnosis. Besides that, the process of 
detecting disease biomarkers requires a high cost and may 
not be feasible to be used in the clinical setting as 
compared to other diagnostic modalities.    
 
CONCLUSION  
 
More cutting-edge technology and equipment have 
greatly advanced the OA study in the hope of developing 
a sustainable method to diagnose early onset of OA. 
Ultimately, these studies hope to arrest this disease before 
it develops further and to finally to uncover a cure for this 
debilitating disease. Engineers will continue to develop 
higher resolution imaging modalities and scientist will 
continue finding new and noble methods to uncover “the 
one” biomarker and eventually piece together the puzzle 
on the pathogenesis of OA. 
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